Valicenti Advisory Services Inc. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 7.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,475 shares of the medical instruments supplier’s stock after selling 125 shares during the period. Valicenti Advisory Services Inc.’s holdings in Becton, Dickinson and Company were worth $356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. WR Wealth Planners LLC grew its holdings in Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares in the last quarter. Clear Creek Financial Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares in the last quarter. Central Pacific Bank Trust Division boosted its holdings in shares of Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 45 shares in the last quarter. Finally, Capital Advisors Ltd. LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 48 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.
Becton, Dickinson and Company Stock Performance
BDX opened at $238.62 on Friday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $262.23. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $68.96 billion, a PE ratio of 52.56, a P/E/G ratio of 1.79 and a beta of 0.42. The firm has a 50 day moving average of $237.33 and a two-hundred day moving average of $235.16.
Analyst Upgrades and Downgrades
BDX has been the topic of a number of recent analyst reports. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and an average price target of $282.63.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
- Five stocks we like better than Becton, Dickinson and Company
- How to Effectively Use the MarketBeat Ratings Screener
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Read Stock Charts for Beginners
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.